Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prop 65 lawsuit?

This article was originally published in The Tan Sheet

Executive Summary

Jarrow Formulas intends to sue SierraSil marketer Sierra Mountain Minerals in January for violations of California's Proposition 65, according to a recent notice letter filed with the state's Attorney General's office. Jarrow alleges that lead, mercury and arsenic levels in the SierraSil ingredient are high enough to require special warning labeling under the state law: roughly 22 times the allowable lead, seven times the allowable mercury and four times the allowable arsenic are present in each daily dose, according to Jarrow. Prop 65 violations have been occurring since at least November 2001, Jarrow adds. The ingredient is available in four products under the SierraSil brand: Joint Formula Powder, Joint Formula, Joint Plus and Osteo Formula. State government officials have 60 days to file a lawsuit in lieu of Jarrow...

You may also be interested in...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts